Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

WGS - GeneDx Holdings Corp. So'nggi Yangiliklar | Finranks

Home

WGS

G

GeneDx Holdings Corp. (WGS)

NMS – Real vaqt narxi. Valyuta: USD

57.09

-4.26 (-6.94%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

57.61

+0.52 (0.91%)

Bozordan keyin: Mar 27, 2026, 7:47 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know

GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know

GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Buy Stocks for March 18th

New Strong Buy Stocks for March 18th

NWPX, INNV, WGS, BCBP and BWXT have been added to the Zacks Rank #1 (Strong Buy) List on March 18, 2026.

Cathie Wood Just Bought This Small Cap Stock Seven Days Straight: Should Investors Take Note?

Cathie Wood Just Bought This Small Cap Stock Seven Days Straight: Should Investors Take Note?

Cathie Wood‘s Ark Invest makes trades across its ETFs every trading day. Those trades are sometimes closely monitored by investors when they involve new stock picks or large trades.

GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

GAITHERSBURG, Md.--(BUSINESS WIRE)--Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing.

WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C

WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C

GeneDx launches Zevra-backed testing program to expand ExomeDx access for Niemann-Pick Type C, aiming to speed diagnosis and add data to its Infinity dataset.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Joby Aviation, GeneDx Holdings, and DraftKings were three of the four stocks that Wood's ETF company bought on Monday. Joby Aviation turned heads late on Monday, after announcing a partnership with the White House that can clear the path for the service to take off in select states later this year.

Videolar

GeneDx CEO on rare disease diagnosis: Earlier testing gives families and clinicians more options

Press-relizlar

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

GAITHERSBURG, Md.--(BUSINESS WIRE)--Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing.

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GAITHERSBURG, Md.--(BUSINESS WIRE)--Announcing GeneDx's new genetic testing program with Zevra Therapeutics to support patients with suspected Niemann–Pick disease type C (NPC).

HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders.

INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.